JP2024527570A5 - - Google Patents
Info
- Publication number
- JP2024527570A5 JP2024527570A5 JP2024500319A JP2024500319A JP2024527570A5 JP 2024527570 A5 JP2024527570 A5 JP 2024527570A5 JP 2024500319 A JP2024500319 A JP 2024500319A JP 2024500319 A JP2024500319 A JP 2024500319A JP 2024527570 A5 JP2024527570 A5 JP 2024527570A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- membered
- pharmaceutically acceptable
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219160P | 2021-07-07 | 2021-07-07 | |
| US63/219,160 | 2021-07-07 | ||
| US202263354017P | 2022-06-21 | 2022-06-21 | |
| US63/354,017 | 2022-06-21 | ||
| PCT/US2022/073522 WO2023283610A1 (en) | 2021-07-07 | 2022-07-07 | Compounds for targeting degradation of irak4 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527570A JP2024527570A (ja) | 2024-07-25 |
| JP2024527570A5 true JP2024527570A5 (https=) | 2025-07-11 |
Family
ID=82748311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500319A Pending JP2024527570A (ja) | 2021-07-07 | 2022-07-07 | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240343733A1 (https=) |
| EP (1) | EP4367113A1 (https=) |
| JP (1) | JP2024527570A (https=) |
| KR (1) | KR20240035526A (https=) |
| AU (1) | AU2022308734A1 (https=) |
| CA (1) | CA3224732A1 (https=) |
| CL (1) | CL2024000020A1 (https=) |
| CO (1) | CO2024001193A2 (https=) |
| IL (1) | IL309941A (https=) |
| JO (1) | JOP20240002A1 (https=) |
| MX (1) | MX2024000395A (https=) |
| TW (1) | TW202321236A (https=) |
| UY (1) | UY39844A (https=) |
| WO (1) | WO2023283610A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| JP7555519B2 (ja) * | 2022-02-14 | 2024-09-24 | アストラゼネカ・アクチエボラーグ | Ｉｒａｋ４阻害剤 |
| WO2024133560A1 (en) * | 2022-12-21 | 2024-06-27 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4389747A1 (en) * | 2022-12-21 | 2024-06-26 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4428134A1 (en) * | 2023-03-10 | 2024-09-11 | Dark Blue Therapeutics Ltd | Protac degraders of mllt1 and/or mllt3 |
| CN120641423A (zh) * | 2023-03-03 | 2025-09-12 | 上海齐鲁制药研究中心有限公司 | Irak4降解剂及其应用 |
| TW202508568A (zh) * | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
| WO2024245331A1 (zh) | 2023-05-30 | 2024-12-05 | 上海汇伦医药股份有限公司 | 三并环类化合物、其制备方法和应用 |
| CN121816348A (zh) | 2023-08-11 | 2026-04-07 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
| AU2024325813A1 (en) * | 2023-08-15 | 2026-03-05 | Guangzhou Imd Pharmaceutical Co., Ltd. | Compound targeting irak protein inhibition or degradation and use thereof |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025106480A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025125575A1 (en) * | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
| CN119019427B (zh) * | 2024-08-14 | 2026-01-20 | 泰诺瑞(天津)生物科技有限责任公司 | 一种三并环类化合物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| GB9208740D0 (en) | 1992-04-23 | 1992-06-10 | Glaxo Group Ltd | Chemical compounds |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| BR112017028269A2 (pt) | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| KR20180132861A (ko) | 2016-04-12 | 2018-12-12 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bet 단백질 분해제 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2018226542A1 (en) | 2017-06-09 | 2018-12-13 | Arvinas, Inc. | Modulators of proteolysis and associated methods of use |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP3658548A1 (en) | 2017-07-28 | 2020-06-03 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| US20190300521A1 (en) | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| IL302595A (en) | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| US20230002361A1 (en) * | 2019-06-27 | 2023-01-05 | Biogen Ma Inc. | 2h-indazole derivatives and their use in the treatment of disease |
| JP7576581B2 (ja) * | 2019-06-27 | 2024-10-31 | バイオジェン・エムエイ・インコーポレイテッド | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるそれらの使用 |
| PH12022500002A1 (en) * | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) * | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| EP4077319A1 (en) | 2019-12-20 | 2022-10-26 | Calico Life Sciences LLC | Protein tyrosine phosphatase degraders and methods of use thereof |
| US20230122219A1 (en) * | 2020-02-03 | 2023-04-20 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AR124451A1 (es) * | 2020-12-22 | 2023-03-29 | Biogen Ma Inc | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES |
| AU2022270089A1 (en) * | 2021-05-03 | 2023-11-16 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
-
2022
- 2022-07-07 EP EP22748718.8A patent/EP4367113A1/en active Pending
- 2022-07-07 JP JP2024500319A patent/JP2024527570A/ja active Pending
- 2022-07-07 MX MX2024000395A patent/MX2024000395A/es unknown
- 2022-07-07 TW TW111125548A patent/TW202321236A/zh unknown
- 2022-07-07 UY UY0001039844A patent/UY39844A/es unknown
- 2022-07-07 KR KR1020247004514A patent/KR20240035526A/ko active Pending
- 2022-07-07 CA CA3224732A patent/CA3224732A1/en active Pending
- 2022-07-07 AU AU2022308734A patent/AU2022308734A1/en active Pending
- 2022-07-07 IL IL309941A patent/IL309941A/en unknown
- 2022-07-07 US US18/576,940 patent/US20240343733A1/en active Pending
- 2022-07-07 WO PCT/US2022/073522 patent/WO2023283610A1/en not_active Ceased
-
2024
- 2024-01-04 JO JOJO/P/2024/0002A patent/JOP20240002A1/ar unknown
- 2024-01-04 CL CL2024000020A patent/CL2024000020A1/es unknown
- 2024-02-05 CO CONC2024/0001193A patent/CO2024001193A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527570A5 (https=) | ||
| JP2024525580A5 (https=) | ||
| AU2022201082B2 (en) | Benzimidazole compounds as c-Kit inhibitors | |
| KR102642408B1 (ko) | 피루브산 키나아제 조절제 및 이의 용도 | |
| US8080561B2 (en) | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | |
| RU2689777C1 (ru) | Конденсированные трициклические производные бензимидазолов в качестве модуляторов активности tnf | |
| JP2023093623A (ja) | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド | |
| KR101859409B1 (ko) | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤 | |
| AU2021285032A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| CN115811977A (zh) | 变构egfr抑制剂及其使用方法 | |
| AU2024207015A1 (en) | Targeted degradation of vav1 | |
| WO2022137085A1 (en) | Indole derivatives useful in treating conditions associated with cgas | |
| JP7854219B2 (ja) | ペプチジルニトリル化合物及びその使用 | |
| KR20150127724A (ko) | 포스포디에스테라제 타입 10a의 신규 억제제 화합물 | |
| CN118974036A (zh) | Raf激酶的抑制剂 | |
| TR201807696T4 (tr) | 5-hidroksi-4-(trifluorometil)pirazolopiridin türevi. | |
| WO2022137082A1 (en) | Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas | |
| JP2026506844A (ja) | Ａｋｔ１の共有結合改質剤およびその使用 | |
| AU2024322339A1 (en) | 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof | |
| CN117500499A (zh) | 经取代的吲哚化合物及其使用方法 | |
| JP7688449B2 (ja) | ピリジン縮合環系化合物とその製造方法、中間体、組成物及び使用 | |
| ES2639956T3 (es) | Compuestos inhibidores de la fosfodiesterasa tipo 10A | |
| WO2015024486A1 (zh) | Dgat1抑制剂及其制备方法和用途 | |
| JP2024543167A (ja) | 三環式誘導体及びその調製方法と使用 | |
| WO2026051746A1 (zh) | 化合物、包含其的药物组合物及其制备方法和用途 |